Guidance, NICE advice and quality standards in development | Guidance

Showing 321 to 330 of 373

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]	Technology appraisal guidance	15 October 2025
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082]	Technology appraisal guidance	15 October 2025
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]	Technology appraisal guidance	17 December 2025
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]	Technology appraisal guidance	20 August 2025
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401	Technology appraisal guidance	TBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance	28 July 2027
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]	Technology appraisal guidance	TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]	Technology appraisal guidance	26 November 2025
Teprotumumab for treating thyroid eye disease [ID6432]	Technology appraisal guidance	13 August 2025
Third molars (impacted) - prophylactic removal [ID898]	Technology appraisal guidance	TBC